Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.01, Zacks reports.
Contineum Therapeutics Trading Down 0.8 %
Shares of NASDAQ CTNM traded down $0.15 during trading hours on Friday, hitting $18.40. The company had a trading volume of 44,394 shares, compared to its average volume of 73,289. Contineum Therapeutics has a 1-year low of $13.27 and a 1-year high of $22.00. The firm’s 50 day moving average is $17.58 and its 200-day moving average is $17.77.
Analysts Set New Price Targets
A number of equities analysts have weighed in on CTNM shares. Robert W. Baird assumed coverage on Contineum Therapeutics in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price target for the company. Royal Bank of Canada reduced their target price on shares of Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Baird R W upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Contineum Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $29.25.
Contineum Therapeutics Company Profile
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
See Also
- Five stocks we like better than Contineum Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 11/4 – 11/8
- Stock Average Calculator
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.